{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Orion SA overvalued or undervalued?
As of October 31, 2025, Orion SA is considered very expensive and overvalued, with a P/E ratio of 7 and an EV to EBITDA of 5.81, despite relatively favorable metrics compared to peers, and has significantly underperformed the S&P 500 with a year-to-date return of -68.97%.
Is Orion SA overvalued or undervalued?
As of October 31, 2025, Orion SA is considered overvalued with a valuation grade of very expensive, reflected in its high P/E ratio of 7 and significant underperformance of -66.43% year-to-date compared to the S&P 500's 16.30% return.
Orion SA Hits New 52-Week Low at USD 5.12 Amidst Declining Performance
Orion SA, a microcap in the specialty chemicals sector, has hit a new 52-week low of USD 5.12, reflecting a 77.46% decline over the past year. The company, with a market cap of USD 596 million, faces challenges including high debt levels and negative quarterly results.
Is Orion SA overvalued or undervalued?
As of October 31, 2025, Orion SA is considered very expensive and overvalued, with a P/E ratio of 7 and significant underperformance compared to the S&P 500, indicating a shift from an attractive valuation.
Is Orion SA overvalued or undervalued?
As of October 31, 2025, Orion SA is considered very expensive and overvalued with a P/E ratio of 7 and a year-to-date return of -66.43%, significantly underperforming compared to its peers and the S&P 500.
Orion SA Hits New 52-Week Low at USD 5.14 Amidst Declining Performance
Orion SA, a microcap in the specialty chemicals sector, has hit a new 52-week low, reflecting a challenging year with a significant stock price decline. The company faces financial stability concerns due to a high debt-to-equity ratio and consecutive quarters of negative results, impacting investor sentiment.
Is Orion SA overvalued or undervalued?
As of October 17, 2025, Orion SA is considered very expensive and overvalued despite having favorable P/E and EV to EBITDA ratios compared to peers, with significant price volatility indicating it may not be a sound investment at its current levels.
Is Orion SA overvalued or undervalued?
As of October 17, 2025, Orion SA is considered very expensive and overvalued based on its financial metrics, including a P/E ratio of 7 and a year-to-date return of -63.58%, contrasting sharply with the S&P 500's positive return of 13.30%.
Is Orion SA overvalued or undervalued?
As of October 17, 2025, Orion SA is considered very expensive and overvalued, with a P/E ratio of 7, an EV to EBITDA ratio of 5.81, and a year-to-date return of -63.58%, significantly underperforming the S&P 500.
Orion SA Stock Plummets to New 52-Week Low of USD 5.23
Orion SA, a microcap in the specialty chemicals sector, has hit a new 52-week low, reflecting a challenging year with a 75.46% decline. The company faces high debt levels, negative operating profit growth, and declining results, while its market capitalization stands at USD 596 million.
Orion SA Stock Plummets to New 52-Week Low at USD 7.00
Orion SA, a microcap in the specialty chemicals sector, has hit a new 52-week low, reflecting a challenging year with a substantial stock price decline. The company faces high debt levels, negative operating profit growth, and declining results, raising concerns about its financial stability and market position.
Orion SA Hits New 52-Week Low at USD 7.03 Amid Declining Performance
Orion SA, a microcap in the specialty chemicals sector, has reached a new 52-week low, reflecting a challenging year with a significant performance decline. The company faces high debt levels and decreasing operating profit, alongside negative results for two consecutive quarters, impacting its financial standing and market capitalization.
Orion SA Stock Plummets to New 52-Week Low of USD 7.09
Orion SA, a microcap in the specialty chemicals sector, has hit a new 52-week low of USD 7.09, down 69.2% over the past year. The company reports a P/E ratio of 7.00, a high debt-to-equity ratio of 2.10, and negative operating profit growth, indicating significant financial challenges.
Orion SA Hits New 52-Week Low at USD 7.12 Amid Significant Decline
Orion SA, a microcap in the specialty chemicals sector, has hit a new 52-week low, reflecting a challenging year with a significant stock price decline. The company faces performance issues, including negative quarterly results, high leverage, and low operating cash flow, impacting its overall financial health.
Orion SA Hits New 52-Week Low at USD 7.32 Amidst Declining Performance
Orion SA, a microcap in the specialty chemicals sector, has hit a new 52-week low of USD 7.32, reflecting a significant decline of 68.82% over the past year. The company has a market cap of USD 596 million, a P/E ratio of 7.00, and faces challenges with high debt levels and negative operating profit growth.
Orion SA Hits 52-Week Low at USD 7.33 Amid Significant Decline
Orion SA, a microcap in the specialty chemicals sector, has hit a new 52-week low, reflecting a substantial decline over the past year. The company faces challenges, including high leverage and negative operating profit growth, while its market capitalization is USD 596 million and P/E ratio is 7.00.
Orion SA Hits New 52-Week Low at USD 7.70 Amid Financial Struggles
Orion SA, a microcap in the specialty chemicals sector, has reached a new 52-week low of USD 7.70, reflecting a 66.91% decline over the past year. The company has a market cap of USD 596 million, a P/E ratio of 7.00, and has reported negative results for two consecutive quarters.
Orion SA Hits New 52-Week Low at USD 7.93 Amidst Declining Performance
Orion SA, a microcap in the specialty chemicals sector, has hit a new 52-week low, experiencing a significant decline over the past year. The company faces challenges with high leverage, negative operating profit growth, and disappointing quarterly results, despite a positive return on equity and trading at a discount to peers.
Orion SA Hits 52-Week Low at USD 8.10 Amidst Declining Performance
Orion SA, a microcap in the specialty chemicals sector, has hit a new 52-week low, reflecting a challenging year with a 65.5% decline in stock price. The company faces high leverage, negative operating profit growth, and declining results, alongside a low valuation compared to peers.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
